Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) for Oxcarbazepine Tablets USP, 150 mg, 300 mg and 600 mg, the company announced through an exchange filing.
Oxcarbazepine is used alone or with other medications to treat seizure disorders (epilepsy). The product will be manufactured at the group’s formulation manufacturing facility in Baddi, Himachal Pradesh (India).
Oxcarbazepine Tablets USP, 150 mg, 300 mg and 600 mg had annual sales of USD 105 mn in the United States (IQVIA MAT May 2023).
The group now has 374 approvals and has so far filed over 442 ANDAs since the commencement of the filing process in FY 2003-04.
1993 Mumbai Bomb Blasts Case: 'Abu Salem Has Not Yet Completed 25-Year Sentence Under Extradition Terms,' Says Bombay HC
Bombay HC Rejects Plea To Set Up ICCs For Advocates Under POSH Act, Says Law Doesn’t Apply Without Employer-Employee Relationship
Bombay HC Issues Contempt Notices To BMC Officials For Demolishing Petitioner’s Home Despite Assurances
₹122 Crore New India Co-operative Bank Scam: Jharkhand Gang Promised Hitesh Mehta 50% Returns; ₹15 Cr Withdrawn Under Pre-Planned Strategy; Reveals EOW Probe
